July 3, 2024

$1.562B

$432M

–

–

$1.13B in development, regulatory, and commercial milestones.

Undisclosed

–

CureVac granted GSK exclusive, worldwide rights to develop and commercialize mRNA vaccine candidates for the prevention of influenza and COVID-19, including combinations.

Development and Commercialization License

License Hand-off

• CureVac granted GSK exclusive, worldwide rights to develop and commercialize mRNA vaccine candidates for influenza and COVID-19 prevention.
• The agreement also covers combination vaccines for these diseases.
• Collaboration between CureVac and GSK began in 2020.
• Vaccine candidates for seasonal influenza and COVID-19 are currently in Phase 2 trials, and a vaccine for avian influenza is in Phase 1.
• GSK will handle all development and commercialization for the vaccine candidates.
• CureVac retains rights to undisclosed preclinically validated infectious disease targets from their earlier collaboration.
• CureVac has the freedom to develop and partner on mRNA vaccines for other infectious diseases or indications independently.
• The new agreement supersedes all previous financial obligations between CureVac and GSK.
• CureVac will receive EUR 400M (approximately $432M) upfront.
• CureVac is also eligible for up to EUR 1.05B (approximately $1.1B) in development, regulatory, and commercial milestones, plus royalties.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.